Clinical Trial Update: A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitamin D Receptor Activator's for Prevention and Treatment of Secondary Hyperparathyroidism

View source ↗

Summary

A completed clinical trial update studying paricalcitol, a selective vitamin D receptor activator, for prevention and treatment of secondary hyperparathyroidism…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Hyperparathyroidism

Drugs mentioned

• Zemplar (Paricalcitol)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Secondary Hyperparathyroidism, End Stage Renal Disease | Status: COMPLETED